

# SB0069S06 compared with SB0069S01

~~{Omitted text}~~ shows text that was in SB0069S01 but was omitted in SB0069S06

inserted text shows text that was not in SB0069S01 but was inserted into SB0069S06

**DISCLAIMER: This document is provided to assist you in your comparison of the two bills. Sometimes this automated comparison will NOT be completely accurate. Therefore, you need to read the actual bills. This automatically generated document could contain inaccuracies caused by: limitations of the compare program; bad input data; or other causes.**

1

**Medication Amendments**  
2025 GENERAL SESSION  
STATE OF UTAH  
**Chief Sponsor: Evan J. Vickers**  
House Sponsor: Steve Eliason



2

3 **LONG TITLE**

4 **General Description:**

5 This bill addresses ~~{interference of pharmacy participation in a federal }~~ the 340B drug discount program.

6 **Highlighted Provisions:**

7 This bill:

9 ▶ defines ~~{terms}~~ a term; ~~{and}~~

10 ▶ prohibits ~~{interfering- }~~ certain conduct by a pharmaceutical manufacturer with ~~{a pharmacy's ability to acquire or dispense certain drugs under a federal }~~ respect to the 340B drug discount program~~{:}~~ ; and

11 ▶ permits the Public Employees' Benefit and Insurance Program to adjust its business practices to mitigate any resulting financial impacts.

13 **Money Appropriated in this Bill:**

14 None

15 **Other Special Clauses:**

16 None

SB0069S01

## SB0069S01 compared with SB0069S06

18 ENACTS:

19 **31A-46-311** , Utah Code Annotated 1953 , Utah Code Annotated 1953

20

21 *Be it enacted by the Legislature of the state of Utah:*

22 Section 1. Section **1** is enacted to read:

23 **31A-46-311. {Protection of pharmacy discount } Prohibited actions with respect to the 340B**  
24 **drug {market} discount program.**

23 {(1) {As used in this section:} }

24 {(a) {"340B drug" means a drug that a 340B entity may purchase at a reduced price pursuant to the  
25 340B drug discount program.} }

26 {(b) {"340B drug discount program" means the federal program limiting drug prices for covered  
27 entities, as described in 42 U.S.C. Sec. 256b et seq.} }

28 {(c) {"340B entity" means an entity authorized to participate in the 340B drug discount program.} }

30 {(d) (1) {"Manufacturer" As used in this section, "manufacturer" means a {drug} pharmaceutical  
31 manufacturer, including an agent or affiliate of a pharmaceutical manufacturer {authorized to  
32 participate in the 340B drug discount program } .

32 {(e) {"Pharmaceutical entity" means:} }

33 {(i) {a 340B entity;} }

34 {(ii) (2) {a} A manufacturer{~~or~~} may not:

35 {(iii) {an agent or affiliate of a 340B entity or manufacturer.} }

36 {(2) (a) {~~A pharmaceutical entity may not~~} directly or indirectly restrict or prohibit:

37 {(a) (i) a pharmacy from contracting with a 340B entity {~~to dispense drugs under the 340B drug~~  
38 discount program } , including by denying the pharmacy access to a drug that is manufactured by the  
39 {~~pharmaceutical entity~~} manufacturer;

40 {(b) (ii) a 340B entity from contracting with a pharmacy {~~to dispense drugs under the 340B drug~~  
41 discount program } , including by denying the 340B entity access to a drug that is manufactured by  
42 the {~~pharmaceutical entity~~} manufacturer;

43 {(e) (iii) the acquisition, dispensing, or delivery of a 340B drug to any location authorized by a 340B  
44 entity to receive the drug, unless prohibited by federal law; or

45

## SB0069S01 compared with SB0069S06

~~{(d)}~~ (iv) a 340B entity from receiving 340B drug discount program pricing for a 340B drug {in accordance with the 340B drug discount program} , including by imposing a time limitation on a 340B entity to replenish or submit a claim for a 340B drug ~~{-}~~ ;

48 ~~{(3)}~~ (b) ~~{A pharmaceutical entity may not}~~ directly or indirectly:

49 ~~{(a)}~~ (i) require a 340B entity to purchase a 340B drug from a supplier if the {pharmaceutical entity} manufacturer would otherwise permit the 340B entity to purchase a drug that is not a 340B drug from the supplier;or

52 ~~{(b)}~~ (ii) require a 340B entity to submit any claim data, utilization data, or information about a 340B entity's contracts with a third-party as a condition for allowing the acquisition of a 340B drug by, or delivery of a 340B drug to, a 340B entity, unless the {sharing of the} data or information sharing is required {under} by federal law; or

56 (c) {otherwise} interfere with:

57 (i) a contract between a pharmacy and a 340B entity; or

58 (ii) the ability of a pharmacy and a 340B entity to enter into a contract {to dispense drugs under the federal 340B drug discount program} .

48 (3) The Public Employees' Benefit and Insurance Program created in Section 49-20-103 may adjust the program's business practices to mitigate any financial impacts resulting from this section.

60 (4) Nothing in this section is to be construed to conflict with federal law.

52 Section 2. **Effective date.**

Effective Date.

This bill takes effect on May 7, 2025.

3-4-25 3:13 PM